Study of the role of cyclobenzaprine in improving neurological deficits after ischemic stroke by inhibiting NLRP3
环泊酚通过抑制NLRP3改善缺血性脑卒中后神经功能障碍的作用研究

摘要

目的 探讨环泊酚通过抑制 NLRP3 炎症小体改善缺血性脑卒中后神经功能障碍的效果及机制。方法 本研究共纳入40例2023年确诊的缺血性脑卒中患者，随机分为两组（n=20）。对照组接受标准化基础治疗，实验组在基础治疗上加用环泊酚（0.5-1.0mg/kg静脉给药），疗程为2周。观察指标包括神经功能缺损程度（NIHSS 评分）、日常生活活动能力（ADL 评分）及血清 NLRP3 水平。结果 治疗后，治疗组 NIHSS 评分显著低于对照组（P<0.05），ADL 评分显著高于对照组（P<0.05），血清 NLRP3 水平显著降低（P<0.05），治疗前各指标差异无统计学意义（P>0.05）。结论 环泊酚可显著改善缺血性脑卒中后神经功能障碍，可能与抑制 NLRP3 炎症小体激活有关，为临床应用提供新证据，但仍需大样本、长期随访研究验证其有效性和安全性。

Abstract

Objective To investigate the effect and mechanism of cyclobenzaprine in improving neurological dysfunction after ischemic stroke by inhibiting NLRP3 inflammatory vesicles.
Methods A total of 40 patients with ischemic stroke diagnosed in 2023 were included in this study and randomly divided into two groups (n=20). The control group received standardized basic treatment, and the experimental group added cyclobenzaprine (0.5-1.0 mg/kg administered intravenously) to the basic treatment for 2 weeks. Observation indexes included the degree of neurological deficit (NIHSS score), the ability to perform activities of daily living (ADL score) and serum NLRP3 level.
Results After treatment, the NIHSS score of the treatment group was significantly lower than that of the control group (P<0.05), the ADL score was significantly higher than that of the control group (P<0.05), and the serum NLRP3 level was significantly lower (P<0.05), and the difference of each index before treatment was not statistically significant (P>0.05).
Conclusion   Cypropofol can significantly improve neurological dysfunction after ischemic stroke, which may be related to the inhibition of NLRP3 inflammatory vesicle activation, providing new evidence for clinical application, but large-sample, long-term follow-up studies are still needed to validate its effectiveness and safety.